SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay.
SARS-CoV-2 detection by a clinical diagnostic RT-LAMP assay.
复制标题
DOI：
10.12688/wellcomeopenres.16517.2
复制
发表时间：
2021
影响因子：
--
通讯作者：
Crick COVID-19 Consortium
中科院分区：
文献类型：
--
作者：
Buck MD;Poirier EZ;Cardoso A;Frederico B;Canton J;Barrell S;Beale R;Byrne R;Caidan S;Crawford M;Cubitt L;Gandhi S;Goldstone R;Grant PR;Gulati K;Hindmarsh S;Howell M;Hubank M;Instrell R;Jiang M;Kassiotis G;Lu WT;MacRae JI;Martini I;Miller D;Moore D;Nastouli E;Nicod J;Nightingale L;Olsen J;Oomatia A;O'Reilly N;Rideg A;Song OR;Strange A;Swanton C;Turajlic S;Wu M;Reis e Sousa C;Crick COVID-19 Consortium
持续的SARS-CoV-2大流行要求采用快速和具有成本效益的方法来准确识别感染者。绝大多数患者样本通过RT-qPCR评估病毒RNA的存在。我们的生物医学研究所与合作伙伴医院和一家经认可的临床诊断实验室合作，建立了一条诊断检测管道，自2020年4月初启动以来，已报告了超过25.2万份RT-qPCR结果。然而，由于对关键资源的持续需求和竞争，人们寻求替代测试策略。在这项工作中，我们提出了一种经临床验证的RT-LAMP高通量SARS-CoV-2检测方法，该方法稳健、可靠、可重复、特异性强且价格低廉。
The ongoing pandemic of SARS-CoV-2 calls for rapid and cost-effective methods to accurately identify infected individuals. The vast majority of patient samples is assessed for viral RNA presence by RT-qPCR. Our biomedical research institute, in collaboration between partner hospitals and an accredited clinical diagnostic laboratory, established a diagnostic testing pipeline that has reported on more than 252,000 RT-qPCR results since its commencement at the beginning of April 2020. However, due to ongoing demand and competition for critical resources, alternative testing strategies were sought. In this work, we present a clinically-validated procedure for high-throughput SARS-CoV-2 detection by RT-LAMP that is robust, reliable, repeatable, specific, and inexpensive.